Natera, Inc. (NASDAQ: NTRA) has reported new molecular residual disease findings from the Phase 3 VOLGA trial in muscle-invasive bladder cancer, showing that circulating tumour DNA status before surgery was strongly associated with subsequent clinical outcomes. Announced on October 27, 2026, the results were presented during a Presidential Symposium at the European Society for Medical Oncology Congress and highlighted the company’s Signatera Genome assay, which incorporates phased and structural genetic variants to support highly sensitive blood-based tumour DNA detection.
The analysis identified three groups with substantially different two-year event-free survival estimates. Patients who remained Signatera-negative had a reported event-free survival rate of 91%, compared with 81% among those who initially tested positive but cleared circulating tumour DNA before surgery and 55% among patients whose tests remained positive. These findings suggest that molecular response during preoperative treatment may provide important prognostic information beyond conventional clinical assessment.
However, the results should not be interpreted as proving that treatment decisions based on Signatera Genome improve survival. VOLGA was a randomised treatment trial that included an exploratory circulating tumour DNA analysis, rather than a study in which treatment allocation was determined by the new assay. Its findings strengthen the case for investigating molecular residual disease-guided treatment strategies but do not independently establish that the assay can identify the optimal therapy for every patient.
What did the Phase 3 VOLGA trial reveal about Signatera Genome and bladder cancer recurrence risk?
The Phase 3 VOLGA trial investigated perioperative treatment strategies for patients with muscle-invasive bladder cancer who were eligible for radical cystectomy but considered unsuitable for cisplatin-based chemotherapy. The trial evaluated combinations involving durvalumab, enfortumab vedotin and, in one investigational arm, tremelimumab. These regimens were compared with radical cystectomy with or without approved adjuvant treatment.
Natera’s technology was used in an associated analysis of circulating tumour DNA dynamics before surgery. Investigators examined whether patients remained molecularly negative, cleared detectable tumour DNA after treatment or continued to have detectable circulating tumour DNA. The objective was to understand how these patterns related to subsequent event-free survival.
The reported differences were substantial. Patients who remained negative had a 91% estimated event-free survival rate at 24 months, while those who achieved clearance after initially testing positive had an 81% rate. Patients with persistent circulating tumour DNA positivity had a considerably lower estimate of 55%.
These results suggest that both the presence of circulating tumour DNA and its change during treatment may be relevant to prognosis. Patients whose molecular findings became negative appeared to have better outcomes than those with persistent positivity. However, the announcement does not provide a complete statistical analysis for every biomarker subgroup, including all relevant confidence intervals and adjusted comparisons.
The findings therefore support an association between molecular status and clinical outcomes rather than establishing a causal relationship. Differences in baseline disease characteristics, treatment response and other factors could contribute to the separation between the groups. Further analysis will be important in determining the extent to which Signatera Genome adds independent prognostic information.
Why could circulating tumour DNA clearance before cystectomy become an important biomarker in muscle-invasive bladder cancer?
Muscle-invasive bladder cancer can recur despite apparently successful local treatment. Radical cystectomy removes the bladder and surrounding tissues as clinically appropriate, but microscopic disease may remain elsewhere in the body. Conventional imaging and pathological assessments cannot always identify these small amounts of residual cancer.
Circulating tumour DNA testing seeks to detect genetic material released by malignant cells into the bloodstream. When the assay identifies tumour-associated genetic changes, a positive result may indicate the persistence of cancer-related material that is not visible through conventional imaging. This creates a potential means of assessing molecular response and recurrence risk.
The VOLGA findings are particularly relevant because the blood measurements were examined before radical cystectomy. Detecting changes during neoadjuvant treatment could potentially provide information about the biological effectiveness of therapy before definitive surgery. That information may eventually help clinicians evaluate which patients require additional treatment or closer surveillance.
However, a negative circulating tumour DNA result does not prove that all malignant cells have been eliminated. Some tumours release relatively little detectable DNA into the bloodstream, while technical limitations and sampling timing can affect results. Patients with negative tests may therefore still experience recurrence.
The distinction between prognosis and treatment selection is also important. A biomarker may accurately identify patients at higher risk without establishing which medicine should be given to reduce that risk. Demonstrating treatment-guiding utility requires evidence that using the test to make therapeutic decisions produces better outcomes than an appropriate alternative strategy.
How does Signatera Genome use phased and structural genetic variants to improve molecular residual disease detection?
Signatera is a tumour-informed molecular residual disease testing platform designed to identify genetic alterations associated with an individual patient’s cancer. Rather than relying exclusively on a fixed set of mutations shared across patients, tumour-informed testing uses information from the patient’s own tumour to develop a personalised molecular monitoring approach. Subsequent blood samples can then be examined for relevant circulating tumour DNA signals.
Signatera Genome extends Natera’s molecular residual disease technology by incorporating phased and structural variants. Phased variants involve genetic alterations that can be analysed in relation to one another, while structural variants include larger changes in genomic organisation. These additional genetic features may increase the information available for distinguishing tumour-derived DNA from background material.
The rationale is particularly relevant when circulating tumour DNA concentrations are very low. Detecting rare tumour-associated fragments requires an assay to distinguish meaningful molecular signals from sequencing errors and other biological noise. Incorporating additional variant classes could potentially improve detection in selected situations, although the magnitude of any advantage must be established through direct comparative validation.
Natera has described Signatera Genome as an ultrasensitive assay, and its inclusion in VOLGA provides evidence of its use within a large clinical development programme. However, the October announcement does not provide a comprehensive head-to-head comparison demonstrating a particular sensitivity advantage over every existing molecular residual disease assay. Claims about analytical superiority would require appropriately controlled testing.
Clinical performance also involves more than analytical sensitivity. A highly sensitive assay must maintain adequate specificity and avoid identifying changes that do not reliably correspond to clinically relevant disease. The relationship between measured molecular signals and patient outcomes ultimately determines whether increased sensitivity produces additional clinical value.
How do the VOLGA treatment results differ from the Signatera Genome biomarker findings?
The broader VOLGA trial generated important evidence concerning perioperative treatment in muscle-invasive bladder cancer. Results published in the New England Journal of Medicine in October 2026 showed that patients receiving durvalumab with neoadjuvant enfortumab vedotin experienced better event-free survival than those assigned to the control strategy. At 24 months, event-free survival was estimated at 63.5% in the treatment group compared with 45.1% in the control group.
The published analysis also reported an overall survival benefit for the durvalumab and enfortumab vedotin regimen. The hazard ratio for death was 0.58, corresponding to a 42% relative reduction in the risk of death during the observed period. The 24-month overall survival estimates were 78.4% and 69.4%, respectively.
A separate treatment group receiving durvalumab, tremelimumab and enfortumab vedotin also demonstrated improved event-free survival compared with the control strategy. However, the two active treatment groups were not formally compared with one another. Safety also required careful consideration, with grade 3 or higher adverse events reported more frequently in the investigational treatment groups than in the control group.
These findings establish the efficacy and safety results of the tested treatment strategies under the trial’s statistical framework. The circulating tumour DNA analysis addresses a related but different question: whether molecular measurements identify patients with different subsequent outcomes. It does not establish that administering or withholding any specific treatment according to Signatera Genome results improves survival.
Separating these evidence categories is important because a successful Phase 3 therapeutic trial does not automatically validate every biomarker investigated within it for clinical decision-making. The VOLGA treatment results and the Signatera Genome prognostic findings are complementary, but their regulatory and clinical implications are not identical.
Why does the earlier IMvigor011 trial provide stronger evidence for MRD-guided treatment decisions?
Natera’s molecular residual disease technology has also been evaluated in the Phase 3 IMvigor011 trial, which directly investigated a circulating tumour DNA-guided treatment strategy after bladder cancer surgery. The study used serial blood testing to identify patients with molecular residual disease who had no radiographic evidence of recurrence. Patients who became circulating tumour DNA-positive were randomised to receive atezolizumab or placebo.
Results published in the New England Journal of Medicine in 2025 demonstrated improved outcomes with atezolizumab among the biomarker-positive population. Median disease-free survival was 9.9 months with treatment compared with 4.8 months with placebo. The hazard ratio for recurrence or death was 0.64, while the hazard ratio for overall mortality was 0.59.
The study enrolled 761 patients, of whom 250 were eligible for randomisation after testing positive. Another 357 patients maintained negative circulating tumour DNA results and did not undergo randomisation to the two treatment groups. Their disease-free survival was reported at 95% at the end of the one-year monitoring period and 88% at two years.
This design provides more direct evidence for biomarker-guided treatment because the molecular test determined which patients entered the randomised therapeutic comparison. It differs from simply observing that patients with positive or negative blood tests have different prognoses. The survival benefit demonstrated among molecularly positive patients supports the clinical relevance of identifying residual disease after surgery.
In May 2026, the United States Food and Drug Administration approved Signatera CDx as a companion diagnostic for identifying eligible muscle-invasive bladder cancer patients who may benefit from atezolizumab-based treatment under the authorised indication. That approval applies to the specified Signatera CDx assay and intended use. It should not be interpreted as blanket FDA approval of every version of Natera’s molecular residual disease technology, including the newer Signatera Genome configuration highlighted in VOLGA.
Could the new Signatera Genome findings influence decisions about treatment before bladder cancer surgery?
One of the potentially important aspects of VOLGA is the timing of the molecular assessment. The Signatera Genome analysis examined circulating tumour DNA before radical cystectomy, creating an opportunity to study molecular response during perioperative treatment. This differs from post-surgical testing, where the primary concern is often identifying residual disease after a tumour has been removed.
If future studies establish that molecular clearance reliably identifies patients with favourable outcomes, clinicians may investigate whether treatment intensity can be adjusted accordingly. Patients with persistent positivity could potentially be considered for additional interventions or more intensive monitoring. Conversely, patients with sustained negative results might become candidates for research into reducing unnecessary treatment exposure.
However, neither approach is established by the reported VOLGA biomarker analysis. A patient who clears circulating tumour DNA may still benefit from completing an effective treatment regimen, while a patient who remains positive may not necessarily benefit from treatment escalation. Altering therapy on the basis of a biomarker requires evidence that the proposed change improves clinical outcomes or avoids treatment burden without unacceptable loss of effectiveness.
The issue is particularly important because perioperative regimens can cause substantial adverse events. In the published VOLGA treatment analysis, serious toxicity was more frequent in the active treatment arms than in the control group. A reliable treatment-selection biomarker could eventually support more individualised decisions, but an incorrect interpretation might expose patients either to unnecessary toxicity or insufficient treatment.
Thomas Powles, principal investigator of VOLGA and chair of Barts Cancer Centre, has highlighted the favourable outcomes observed among patients who remained molecularly negative or cleared their circulating tumour DNA before surgery. His interpretation supports further investigation of molecular response as a treatment decision tool. The practical value of that approach will depend on prospective studies designed specifically to test biomarker-guided treatment strategies.
What do Natera’s other ESMO 2026 findings reveal about the wider development of molecular residual disease testing?
Natera reported that its oncology testing technologies featured in 25 abstracts at the 2026 European Society for Medical Oncology Congress, including nine oral presentations. The company also highlighted concurrent publications in Nature Medicine and ESMO Open. These findings illustrate how molecular residual disease research is expanding beyond a single tumour type into multiple treatment settings.
In the MDT-Bridge lung cancer study, researchers evaluated Natera’s Clarity assay using phased variant technology in patients with resectable stage IIB to IIIB non-small-cell lung cancer. The assay detected circulating tumour DNA before treatment in 99% of the evaluated population. Molecular clearance during neoadjuvant therapy was associated with pathological response and subsequent event-free survival outcomes.
Natera reported that clearance by the second treatment cycle had an 83% predictive value for pathological complete response. It also stated that patients achieving molecular clearance before surgery or chemoradiotherapy had 100% one-year event-free survival in the reported analysis. These observations are relevant to response monitoring, but the percentages must be interpreted in relation to the study population, sample size and follow-up duration.
The KEYNOTE-B21 endometrial cancer analysis provided another example of molecular residual disease assessment after surgery. Approximately 20% of patients with resected high-risk disease were Signatera-positive, while negative molecular status had a reported 97% negative predictive value for disease-specific events in the pembrolizumab group. The findings suggest that molecular testing may help characterise recurrence risk, although its use to select treatment requires indication-specific evidence.
Natera also highlighted findings from the HER2-CR breast cancer study, in which 81% of exceptional responders with HER2-positive metastatic disease maintained molecular residual disease negativity during serial monitoring. The company presented this as supporting further investigation of treatment de-escalation strategies. However, maintained molecular negativity does not establish that treatment can safely be withdrawn or reduced without affecting disease control.
How could expanding clinical evidence influence reimbursement and hospital adoption of Signatera testing?
Molecular residual disease testing is becoming increasingly relevant to oncology service planning because it offers information beyond conventional imaging and pathological staging. However, broad clinical adoption requires a combination of analytical performance, demonstrated clinical utility and an appropriate reimbursement pathway. Evidence supporting one clinical use does not automatically establish coverage for every tumour type or treatment setting.
Natera’s existing regulatory and commercial experience provides an important foundation. The FDA approval of Signatera CDx for a specified bladder cancer companion diagnostic use demonstrates that molecular residual disease testing can support a defined treatment-selection pathway. The newer Signatera Genome technology will require evidence and regulatory consideration appropriate to its intended applications.
Hospitals and oncology practices must also assess implementation requirements. Tumour-informed assays can require suitable tumour tissue, genomic analysis, blood collection and coordination between laboratories and treating clinicians. Turnaround time becomes especially important when results are intended to influence decisions before surgery or during a defined treatment window.
Payers are likely to examine whether testing changes patient management in a way that improves outcomes or reduces unnecessary expenditure. Prognostic information can be clinically useful, but reimbursement decisions may depend on whether it leads to measurable treatment benefits. The strongest evidence will generally come from studies that incorporate the biomarker into a clearly defined clinical decision strategy.
These considerations are relevant to Signatera Genome because improvements in molecular detection could increase the number of patients classified according to residual disease status. The commercial significance of greater sensitivity will depend on whether those additional classifications are clinically actionable. More positive results do not necessarily create value unless the information supports better decisions.
What does the ESMO 2026 evidence mean for Natera’s oncology business and investor expectations?
Natera’s latest molecular residual disease findings add to a period of significant growth in its oncology testing operations. In the second quarter of 2026, the company processed approximately 296,700 oncology tests, compared with approximately 188,800 during the corresponding quarter of 2025. This represented year-on-year growth of 57.2%, indicating increasing utilisation across its oncology portfolio.
Total quarterly revenue increased by 37.7% to $752.8 million from $546.6 million a year earlier. The company also reported that clinical molecular residual disease oncology units increased by 34,000 sequentially, its largest quarter-on-quarter expansion at that time. These figures demonstrate commercial momentum, although they do not isolate the contribution of the newly presented Signatera Genome research.
Natera also raised its full-year 2026 revenue guidance in August to a range of $2.85 billion to $2.91 billion. The guidance reflected expectations for the broader business rather than revenue attributable specifically to the VOLGA biomarker results. The October ESMO announcement should therefore be understood primarily as an evidence-development and potential market-expansion event.
For investors, the clinical significance of the findings lies in the possibility that molecular residual disease testing could become relevant at additional decision points across oncology. Stronger evidence could support future regulatory applications, reimbursement expansion and increased testing utilisation. However, those outcomes remain dependent on indication-specific validation and the demonstration of clinical utility.
The VOLGA findings add important prognostic evidence by showing a clear relationship between circulating tumour DNA dynamics and event-free survival before bladder cancer surgery. Their next clinical test will be whether this information can be incorporated into prospectively validated treatment strategies that improve outcomes. For Natera, translating increasingly sensitive molecular detection into actionable and reimbursed clinical decisions will remain the defining requirement for further expansion of its oncology business.
